The data behind OncoBEAM™

Evaluating the efficacy of BEAMing technology

Proven performance

Multiple independent clinical studies found that OncoBEAM™ accurately detects and quantifies various mutations related to non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. For your convenience, we’ve made those studies accessible from this page.

BEAMing technology

  1. Denis, J.A., Guillerm, E., Coulet, F., Larsen, A.K., Lacorte, J.-M., 2017. The Role of BEAMingand Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. Mol Diagn Ther. doi: 10.1007/s40291-017-0287-7
  2. Medina Diaz, I., Nocon, A., Mehnert, D.H., Fredebohm, J., Diehl, F., Holtrup, F., 2016. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS ONE 11, e0166354. doi: 10.1371/journal.pone.0166354
  3. Diehl, Frank, and Luis A. Diaz. 2007. “Digital Quantification of Mutant DNA in Cancer Patients.” Current Opinion in Oncology19 (1): 36–42. doi: 10.1097/CCO.0b013e328011a8e7.
  4. Diehl, Frank, Meng Li, Yiping He, Kenneth W. Kinzler, Bert Vogelstein, and Devin Dressman. 2006. “BEAMing: Single-Molecule PCR on Microparticles in Water-in-Oil Emulsions.” Nature Methods 3 (7): 551–59. doi:10.1038/nmeth898.
  5. Li, Meng, Frank Diehl, Devin Dressman, Bert Vogelstein, and Kenneth W. Kinzler. 2006. “BEAMing up for Detection and Quantification of Rare Sequence Variants.” Nature Methods 3 (2): 95–97. doi:10.1038/nmeth850.
  6. Diehl, Frank, Meng Li, Yiping He, Kenneth W. Kinzler, Bert Vogelstein, and Devin Dressman. 2006. “BEAMing: Single-Molecule PCR on Microparticles in Water-in-Oil Emulsions.” Nature Methods 3 (7): 551–59. doi:10.1038/nmeth898.
  7. Dressman, Devin, Hai Yan, Giovanni Traverso, Kenneth W. Kinzler, and Bert Vogelstein. 2003. “Transforming Single DNA Molecules into Fluorescent Magnetic Particles for Detection and Enumeration of Genetic Variations. Proceedings of the National Academy of Sciences of the United States of America 100 (15): 8817–22. doi:10.1073/pnas.1133470100.


  1. Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C.-H., Barrett, J.C., Jänne, P.A., 2016. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 34, 3375–3382. doi: 10.1200/JCO.2016.66.7162
  2. Paz-Ares, Luis, Vera Hirsh, Li Zhang, Filippo de Marinis, James Chih-Hsin Yang, Heather A. Wakelee, Takashi Seto, et al. 2015. “MISSION Trial – A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Non-Squamous NSCLC after 2 or 3 Previous Treatment Regimens.” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, November. doi:10.1097/JTO.0000000000000693.
  3. Karlovich, Chris A., Jonathan Goldman, Jong-Mu Sun, Elaina Mann, Lecia V. Sequist, Krzysztof Konopa, Wei Wen, et al. 2016. “Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase 1 Study of Rociletinib (CO-1686).”  Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, January. doi:10.1158/1078-0432.CCR-15-1260.
  4. Thress, Kenneth S., Roz Brant, T. Hedley Carr, Simon Dearden, Suzanne Jenkins, Helen Brown, Tracey Hammett, Mireille Cantarini, and J. Carl Barrett. 2015. “EGFR Mutation Detection in ctDNA from NSCLC Patient Plasma: A Cross-Platform Comparison of Leading Technologies to Support the Clinical Development of AZD9291.” Lung Cancer (Amsterdam, Netherlands), October. doi:10.1016/j.lungcan.2015.10.004.
  5. Piotrowska, Zofia, Matthew J. Niederst, Chris A. Karlovich, Heather A. Wakelee, Joel W. Neal, Mari Mino-Kenudson, Linnea Fulton, et al. 2015. “Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.” Cancer Discovery, May. doi:10.1158/2159-8290.CD-15-0399.
  6. Thress, K., J. C. Yang, M. Ahn, D. Kim, S. Kim, Y. Ohe, D. Planchard, et al. 2014. “Levels of Egfr T790m in Plasma Dna as a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor (1270p).” Annals of Oncology 25 (suppl 4): iv446–47. doi:10.1093/annonc/mdu349.49.
  7. Goldman, Jonathan W., Chris Karlovich, Elaina Mann, Lindsey Rolfe, Shannon Matheny, Darrin Despain, Philipp Angenendt, et al. 2015. “Abstract 927: Pretreatment and Serial Plasma Assessments of EGFR Mutations in NSCLC Patients Treated with Rociletinib (CO-1686).” Cancer Research 75 (15 Supplement): 927–927. doi:10.1158/1538-7445.AM2015-927.
  8. Sequist, Lecia V., Jonathan Wade Goldman, Heather A. Wakelee, D. Ross Camidge, Helena Alexandra Yu, Andrea Varga, Ben Solomon, et al. 2015. “Efficacy of Rociletinib (CO-1686) in Plasma-Genotyped T790M-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pts).” ASCO Meeting Abstracts 33 (15_suppl): 8001.

BEAMing in CRC

  1. Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., Twomey, B., Bach, B.A., Jung, A.S., Bardelli, A., 2017. Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer. Ann. Oncol. doi:10.1093/annonc/mdx504
  2. García-Foncillas, J., Alba, E., Aranda, E., Díaz-Rubio, E., López-López, R., Tabernero, J., Vivancos, A. 2017 Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. doi:10.1093/annonc/mdx501
  3. Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J.M., Paéz, D., Falcó, E., Lopez Lopez, C., Aranda, E., Jones, F., Sikri, V., Nuciforo, P., Fasani, R., Tabernero, J., Montagut, C., Azuara, D., Dienstmann, R., Salazar, R., Vivancos, A., 2017. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. doi: 10.1093/annonc/mdx112
  4. Vidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., Vidal, Y., Candamio, S., Vázquez, F., Ruiz, J., Guix, M., Visa, L., Sikri, V., Albanell, J., Bellosillo, B., López, R., Montagut, C., 2017. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann. Oncol. doi: 10.1093/annonc/mdx125
  5. Trojan, J., rg, Klein-Scory, S., Koch, C., Schmiegel, W., Baraniskin, A., 2017. Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer. Case Reports in Oncological Medicine. doi:10.1155/2017/6139634
  6. Schmiegel, W., Scott, R.J., Dooley, S., Lewis, W., Meldrum, C.J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., Lucas, A., Shi, E., Namdarian, K., Chan, T., Acosta, D., Ping-Chang, S., Tannapfel, A., Reinacher-Schick, A., Uhl, W., Teschendorf, C., Wolters, H., Stern, J., Viebahn, R., Friess, H., Janssen, K.-P., Nitsche, U., Slotta-Huspenina, J., Pohl, M., Vangala, D., Baraniskin, A., Dockhorn-Dworniczak, B., Hegewisch-Becker, S., Ronga, P., Edelstein, D.L., Jones, F.S., Hahn, S., Fox, S.B., 2017. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol 11, 208–219. doi: 10.1002/1878-0261.12023
  7. Toledo, R.A., Cubillo, A., Vega, E., Garralda, E., Alvarez, R., de la Varga, L.U., Pascual, J.R., Sánchez, G., Sarno, F., Prieto, S.H., Perea, S., Lopéz-Casas, P.P., López-Ríos, F., Hidalgo, M., 2016. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. doi:10.18632/oncotarget.13311 doi: 10.18632/oncotarget.13311
  8. Tabernero, Josep, Heinz-Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Marc Ychou, Yves Humblet, et al. 2015. “Analysis of Circulating DNA and Protein Biomarkers to Predict the Clinical Activity of Regorafenib and Assess Prognosis in Patients with Metastatic Colorectal Cancer: A Retrospective, Exploratory Analysis of the CORRECT Trial.” The Lancet. Oncology 16 (8): 937–48. doi:10.1016/S1470-2045(15)00138-2.
  9. Siravegna, Giulia, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, et al. 2015. “Clonal Evolution and Resistance to EGFR Blockade in the Blood of Colorectal Cancer Patients.” Nature Medicine 21 (7): 795–801. doi:10.1038/nm.3870.
  10. Scott, R., S. Dooley, W. Lewis, C. Meldrum, P. Pockney, B. Draganic, S. Smith, et al. 2015. “P-273Concordance of RAS Mutation Status in CRC Patients by Comparison of Results from Circulating Tumour DNA and Tissue-Based Testing.” Annals of Oncology 26 (suppl 4): iv80–81. doi:10.1093/annonc/mdv233.270.  or available at Annals of Oncology
  11. Van Cutsem, Eric, Heinz-Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, Ivan Melezínek, Frank Beier, et al. 2015. “Fluorouracil, Leucovorin, and Irinotecan plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 33 (7): 692–700. doi:10.1200/JCO.2014.59.4812.
  12. Bokemeyer, C., C.-H. Köhne, F. Ciardiello, H.-J. Lenz, V. Heinemann, U. Klinkhardt, F. Beier, K. Duecker, J. H. van Krieken, and S. Tejpar. 2015. “FOLFOX4 plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer.” European Journal of Cancer (Oxford, England: 1990), April. doi:10.1016/j.ejca.2015.04.007.
  13. Morelli, M. P., M. J. Overman, A. Dasari, S. M. A. Kazmi, T. Mazard, E. Vilar, V. K. Morris, et al. 2015. “Characterizing the Patterns of Clonal Selection in Circulating Tumor DNA from Patients with Colorectal Cancer Refractory to Anti-EGFR Treatment.” Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 26 (4): 731–36. doi:10.1093/annonc/mdv005.
  14. Lenz, H., D. Niedzwiecki, F. Innocenti, C. Blanke, M. R. Mahony, B. H. O’Neil, J. E. Shaw, et al. 2014. “501ocalgb/Swog 80405: Phase Iii Trial of Irinotecan/5-Fu/Leucovorin (folfiri) or Oxaliplatin/5-Fu/Leucovorin (mfolfox6) with Bevacizumab (bv) or Cetuximab (cet) for Patients (pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon or Rectum (mcrc).” Annals of Oncology 25 (suppl 4): mdu438.13. doi:10.1093/annonc/mdu438.13.
  15. Misale, Sandra, Sabrina Arena, Simona Lamba, Giulia Siravegna, Alice Lallo, Sebastijan Hobor, Mariangela Russo, et al. 2014. “Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer.” Science Translational Medicine 6 (224): 224ra26. doi:10.1126/scitranslmed.3007947.
  16. Diaz, Luis A., Richard T. Williams, Jian Wu, Isaac Kinde, J. Randolph Hecht, Jordan Berlin, Benjamin Allen, et al. 2012. “The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers.” Nature 486 (7404): 537–40. doi:10.1038/nature11219.
  17. Misale, Sandra, Rona Yaeger, Sebastijan Hobor, Elisa Scala, Manickam Janakiraman, David Liska, Emanuele Valtorta, et al. 2012. “Emergence of KRAS Mutations and Acquired Resistance to Anti-EGFR Therapy in Colorectal Cancer.” Nature 486 (7404): 532–36. doi:10.1038/nature11156.
  18. Holdhoff, M., Schmidt, K., Donehower, R., Diaz, L.A., 2009. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl. Cancer Inst. 101, 1284–1285.
  19. Diehl, Frank, Kerstin Schmidt, Michael A Choti, Katharine Romans, Steven Goodman, Meng Li, Katherine Thornton, et al. 2008. “Circulating Mutant DNA to Assess Tumor Dynamics.” Nature Medicine 14 (9): 985–90. doi:10.1038/nm.1789.
  20. Diehl, Frank, Kerstin Schmidt, Kristine H. Durkee, Kent J. Moore, Steve N. Goodman, Anthony P. Shuber, Kenneth W. Kinzler, and Bert Vogelstein. 2008. “Analysis of Mutations in DNA Isolated from Plasma and Stool of Colorectal Cancer Patients.” Gastroenterology 135 (2): 489–98. doi:10.1053/j.gastro.2008.05.039.
  21. Diehl, Frank, Meng Li, Devin Dressman, Yiping He, Dong Shen, Steve Szabo, Luis A. Diaz, et al. 2005. “Detection and Quantification of Mutations in the Plasma of Patients with Colorectal Tumors.” Proceedings of the National Academy of Sciences of the United States of America 102 (45): 16368–73. doi:10.1073/pnas.0507904102.

BEAMing in melanoma and other cancers

  1. Spoerke, J.M., Gendreau, S., Walter, K., Qiu, J., Wilson, T.R., Savage, H., Aimi, J., Derynck, M.K., Chen, M., Chan, I.T., Amler, L.C., Hampton, G.M., Johnston, S., Krop, I., Schmid, P., Lackner, M.R., 2016. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7, 11579. doi:10.1038/ncomms11579
  2. Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G.V., Schadendorf, D., Flaherty, K., Kefford, R., Hauschild, A., Hwu, P., Haney, P., O’Hagan, A., Carver, J., Goodman, V., Legos, J., Martin, A.-M., 2016. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin. Cancer Res. 22, 567–574. doi: 10.1158/1078-0432.CCR-15-0321
  3. Janku, Filip, Philipp Angenendt, Apostolia M. Tsimberidou, Siqing Fu, Aung Naing, Gerald S. Falchook, David S. Hong, et al. 2015. “Actionable Mutations in Plasma Cell-Free DNA in Patients with Advanced Cancers Referred for Experimental Targeted Therapies.” Oncotarget 6 (14): 12809–21.  PMID:  25980577
  4. Bettegowda, Chetan, Mark Sausen, Rebecca J. Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, et al. 2014. “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies.” Science Translational Medicine 6 (224): 224ra24. doi:10.1126/scitranslmed.3007094.
  5. Lipson, Evan J., Victor E. Velculescu, Theresa S. Pritchard, Mark Sausen, Drew M. Pardoll, Suzanne L. Topalian, and Luis A. Diaz. 2014. “Circulating Tumor DNA Analysis as a Real-Time Method for Monitoring Tumor Burden in Melanoma Patients Undergoing Treatment with Immune Checkpoint Blockade.” Journal for Immunotherapy of Cancer 2 (1): 42. doi:10.1186/s40425-014-0042-0.
  6. Yoo, C., M.-H. Ryu, Y. S. Na, B.-Y. Ryoo, S. R. Park, and Y.-K. Kang. 2014. “Analysis of Serum Protein Biomarkers, Circulating Tumor DNA, and Dovitinib Activity in Patients with Tyrosine Kinase Inhibitor-Refractory Gastrointestinal Stromal Tumors.” Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 25 (11): 2272–77. doi:10.1093/annonc/mdu386.
  7. Ascierto, Paolo A., David Minor, Antoni Ribas, Celeste Lebbe, Anne O’Hagan, Niki Arya, Mary Guckert, et al. 2013. “Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients with Metastatic Melanoma.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 (26): 3205–11. doi:10.1200/JCO.2013.49.8691.
  8. Higgins, Michaela J., Danijela Jelovac, Evan Barnathan, Brian Blair, Shannon Slater, Penny Powers, Jane Zorzi, et al. 2012. “Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 (12): 3462–69. doi:10.1158/1078-0432.CCR-11-2696.